Early Initiation of Menstruation May Influence Breast Cancer Risk in Black Women

Share this content:
Age at menarche could play a role in development of estrogen receptor-negative (ER−) breast cancers among African-American women.
Age at menarche could play a role in development of estrogen receptor-negative (ER−) breast cancers among African-American women.

Age at menarche could play a role in development of estrogen receptor-negative (ER−) breast cancers among African-American women, according to a study published in the Journal of the National Cancer Institute.

Christine B. Ambrosone, Ph.D., from the Roswell Park Cancer Institute in Buffalo, N.Y., and colleagues analyzed data gathered from the AMBER Consortium (4,426 African-American women with breast cancer and 17,474 controls).

The authors performed polytomous logistic regression to estimate odds ratios (ORs) for ages at menarche and first live birth (FLB), and the interval between, in relation to ER+ and ER− breast cancer.

The researchers found that risk of ER− breast cancer was reduced with later age at menarche among both parous and nulliparous women (≥15 versus <11 years; ORs, 0.62 [95 percent confidence interval, 0.48 to 0.81] and 0.56 [95 percent confidence interval, 0.29 to 1.10], respectively), with no effect of age at FLB. The inverse association was weaker among nulliparous women with ER+ breast cancer.

RELATED: Risk Assessment Identifies Women at High Risk of Breast Cancer

Longer intervals between menarche and FLB were associated with increased risk of ER+ breast cancer in a dose-response manner (OR for 20 year interval, 1.39; Ptrend = 0.003); however, ER− risk was only increased for intervals up to 14 years (Ptrend = 0.33).

"These findings indicate that etiologic pathways involving adolescence and pregnancy may differ for ER− and ER+ breast cancer," the authors write.

Reference

  1. Ambrosone CB, Zirpoli G, Hong CC, et al. Important Role of Menarche in Development of Estrogen Receptor–Negative Breast Cancer in African American Women. Journal of the National Cancer Institute. doi: 10.1093/jnci/djv172. May 22, 2015.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs